HCV Management Program Offers Triple Therapy Regimen

[Guest guest]

HCV Management Program Offers Triple Therapy Regimen

Because they offer hope of an improved success rate, Axium's HEPVisionsSM Program now includes the two recently approved drugs into Hepatitis C treatment.

New Hepatitis C Drugs to their HEPVisionsSM Therapy Management Program

(OPENPRESS) June 14, 2011 -- The announcement comes on the heels of the FDA's approval of Merck's VictrelisTM and Vertex's IncivekTM. Both drugs are approved for use in combination with peg interferon and ribavirin, creating a triple therapy regimen. Clinical trials have shown that using one of the two new drugs along with peg interferon and ribavirin drugs is more effective at producing a sustained virological response (SVR).

"Axium is pleased to add VictrelisTM and IncivekTM to the HEPVisionsSM program," said Mark Montgomery, President and CEO of Axium Healthcare Pharmacy. "The new triple therapy regimen is complex and expensive. Careful patient education, monitoring, and adherence are keys to successful treatment."

Continue reading this entire article:http://www.theopenpress.com/index.php?a=press & id=107323

http://www.hepatitis-central.com/mt/archives/2011/06/hcv_management.html